GLP-2 Peptide Research: Teduglutide Pharmacology, Intestinotrophic Mechanisms, and Gut Barrier Evidence

GLP-2 is a 33-residue proglucagon-derived intestinotrophic hormone that drives crypt cell proliferation and suppresses crypt apoptosis through the GLP-2 receptor, and GLP-2 peptide research turns on one structural fact: the receptor is not on the enterocytes that grow. It sits on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells, so the trophic signal reaches the epithelium through paracrine intermediaries, with insulin-like growth factor 1 as the essential one. Teduglutide, the DPP-IV-resistant [Gly2] analogue, is the standard research tool because native GLP-2 is cleaved too quickly for consistent exposure in several species. Teduglutide is a reference compound discussed here for its pharmacology; it is not an item in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Discovery and the DPP-IV Problem

GLP-2 was identified as the intestinotrophic factor by Drucker and colleagues in the Proceedings of the National Academy of Sciences (1996, 93:7911-7916, PMID 8755576), not in the Journal of Biological Chemistry as an earlier version of this page stated. Nude mice bearing subcutaneous proglucagon-producing tumours showed marked small intestinal epithelial proliferation, and the responsible factor was a 33-residue peptide with no previously ascribed function. GLP-2 administration stimulated crypt cell proliferation and increased bowel weight and villus growth in jejunum and ileum within four days.

The analogue exists because of a species-dependence result that is worth understanding rather than skipping. In Nature Biotechnology (1997, 15:673-677, PMID 9219272), GLP-2 that was strongly intestinotrophic in mice increased villus height in rats but produced no gain in small bowel weight at all. The explanation was dipeptidyl peptidase IV. GLP-2(1-33) was degraded to GLP-2(3-33) by human placental DPP-IV and by rat serum, but not by serum from DPP-IV-deficient rats, and rat GLP-2 given to DPP-IV-deficient rats produced a significant increase in small bowel weight. A synthetic analogue with alanine at position 2 replaced by glycine, r[Gly2]GLP-2, resisted cleavage by both DPP-IV and rat serum and produced a significant increase in small bowel mass in wild-type rats.

The direction of that substitution matters and an earlier version of this page had it inverted, describing the native peptide as carrying Gly2. Native GLP-2 begins His-Ala, and alanine at position 2 is exactly what makes it a DPP-IV substrate. The analogue carries glycine there, which is why it is resistant. Half-life figures of roughly seven minutes and 1.3 hours previously given on this page were not traceable to a located source and have been removed; the published basis for the analogue is the resistance to cleavage and the resulting intestinotrophic activity, not a specific number.

Receptor Localisation and the Paracrine Mechanism

The GLP-2 receptor is a class B G protein-coupled receptor coupling to Gs and raising intracellular cyclic AMP. Its cellular distribution is the reason the mechanism is indirect. Guan and colleagues (Gastroenterology 2006, 130:150-164, PMID 16401478) localised the receptor in human and pig tissue by laser capture microdissection with quantitative RT-PCR, fluorescence in situ hybridisation and validated antibody immunostaining. Receptor protein co-localised with serotonin in enteroendocrine cells and with endothelial nitric oxide synthase-expressing and vasoactive intestinal polypeptide-positive enteric neurons, with mRNA in villus epithelium and myenteric plexus. The review of what has been called the cryptic mechanism of GLP-2 action (American Journal of Physiology, Gastrointestinal and Liver Physiology 2011, 301:G1-G8, PMID 21527727) sets out the resulting paracrine model.

Insulin-like growth factor 1 is the mediator with the strongest genetic evidence behind it. Dubé and colleagues (Gastroenterology 2006, 131:589-605, PMID 16890611) showed that GLP-2 increases IGF-1 mRNA and IGF-1 secretion in GLP-2-responsive primary intestinal cultures and increases intestinal IGF-1 mRNA in vivo, and then tested necessity directly. Wild-type mice responded to 0.1 micrograms per gram per day of GLP-2 with increased intestinal weight, morphometry and proliferative indices, while Igf1 null mice were unresponsive at the same dose, showing no change in weight, morphometry or proliferation. A tenfold higher dose produced an effect in the null animals only on small intestinal weight normalised to body weight, and Igf2 hypomorphs showed a partially impaired response. Both genotypes grew normally in response to IGF-1 itself or to R-spondin1, so the defect is specifically in transducing the GLP-2 signal. The follow-up work (Endocrinology 2008, 149:291-301, PMID 17884945) placed beta-catenin signalling downstream in the crypt. An earlier version of this page attributed a 60 percent reduction in proliferation with an IGF-1 receptor blocking antibody to a 2004 Leen study that could not be located; the knockout data above is both stronger and traceable.

More recent work has resolved which cells respond. In Lgr5-eGFP reporter mice (Cellular and Molecular Gastroenterology and Hepatology 2022, 13:1829-1842, PMID 35218981), acute human [Gly2]-GLP-2 raised the proportion of eGFP-positive EdU-positive intestinal stem cells by 11 to 22 percent, increased the ratio of cells in early to late S-phase by 97 percent and the proportion entering S-phase by 218 percent, and raised Mcm3 expression in Lgr5-expressing cells by 122 percent. The receptor antagonist GLP-2(3-33) moved the same measures in the opposite direction. Chronic treatment increased OLFM4-positive cells per crypt, and that chronic effect required the intestinal epithelial IGF-1 receptor, which ties the acute and chronic arms of the mechanism together.

Mucosal Protection in Injury Models

Two injury models establish the anti-apoptotic side of the pharmacology. In indomethacin-induced murine enteritis (American Journal of Physiology 1999, 277:E937-E947, PMID 10567023), human [Gly2]GLP-2 improved survival whether given before, with or after indomethacin, and reduced histological disease activity, intestinal ulceration and small bowel myeloperoxidase activity. It also reduced cytokine induction, bacteraemia and the proportion of positive splenic and hepatic bacterial cultures, increased crypt cell proliferation and reduced crypt apoptosis. In chemotherapy-induced mucositis (Cancer Research 2001, 61:687-693, PMID 11212269), the same analogue improved survival, reduced bacteraemia, attenuated epithelial injury and inhibited crypt apoptosis after irinotecan or 5-fluorouracil, without impairing chemotherapy effectiveness in tumour-bearing mice. In cells transfected with the GLP-2 receptor it reduced activation of caspase-8 and caspase-3 and inhibited PARP cleavage, which locates the anti-apoptotic action at the receptor rather than downstream of a tissue-level effect. Dextran sodium sulphate colitis percentages previously given on this page were not traceable and have been replaced by these two datasets.

Barrier Function and Paracellular Permeability

The permeability literature contains a result that is frequently reported backwards, so it is worth stating precisely. In rats (Digestive Diseases and Sciences 2020, 65:2605-2618, PMID 32006214), paracellular permeability was measured as appearance of intraduodenally perfused FITC-dextran 4000 in the portal vein after lipopolysaccharide. Permeability rose at six hours but not at one or three hours, accompanied by rising portal GLP-2 levels and increased ileal proglucagon and pro-inflammatory cytokine mRNA, and co-treatment with a GLP-2 receptor antagonist made permeability worse, which shows that endogenous GLP-2 release is itself part of the defence. Exogenous GLP-2 given six or twelve hours after lipopolysaccharide reduced permeability, and teduglutide given at three or six hours reduced FITC-dextran uptake measured at six hours.

The mechanism reported is not the IGF-1 axis. The teduglutide effect was reversed by the VPAC1 antagonist PG97-269 and by the nitric oxide synthase inhibitor L-NAME, and was not reversed by EGF or IGF-1 receptor inhibitors. An earlier version of this page stated that the barrier effect was blocked by PI3K inhibition and was therefore downstream of the GLP-2 receptor and IGF-1, which is the opposite of the published finding. The VPAC1 and nitric oxide dependence is consistent with the receptor localisation work above, where the receptor sits on vasoactive intestinal polypeptide-positive and eNOS-expressing enteric neurons. Acute barrier and vascular actions run through the neural and vasoactive arm; chronic growth runs through IGF-1.

Blood Flow and the Vascular Arm

The vascular response is rapid and mechanistically separate from the trophic one. In neonatal pigs on total parenteral nutrition, GLP-2 infusion dose-dependently stimulated intestinal blood flow with coordinate upregulation of intestinal eNOS mRNA, protein and Ser1177 phosphorylation (Guan 2006, PMID 16401478). More recent work in male rats (Physiological Reports 2025, 13:e70699, PMID 41388842) confirms an acute increase in superior mesenteric artery blood flow. An earlier version of this page attributed mucosal VEGF-A fold changes, capillary density percentages and a correlation coefficient to a 2019 Peptides paper by Nakamura that could not be located, and described Doppler confirmation in rats and dogs. Those claims have been removed; the documented species are pig and rat, and the documented mediator is nitric oxide rather than VEGF.

Short Bowel Syndrome and Translation

GLP-2 is one of the few peptides in this literature with controlled human data, which constrains what the animal work can be said to predict. Jeppesen and colleagues (Gastroenterology 2001, 120:806-815, PMID 11231933) studied eight short bowel patients without terminal ileum or colon and with no postprandial GLP-2 secretion, using balance studies before and after 35 days of native GLP-2. Energy absorption improved from 49.9 to 53.4 percent, wet weight absorption from 25 to 36 percent and nitrogen absorption from 47.4 to 52.1 percent, all at P equal to 0.04. Body weight rose 1.2 kg and lean body mass 2.9 kg while fat mass fell 1.8 kg. Time to 50 percent gastric emptying of solids increased by 30 minutes while small bowel transit time was unchanged, and crypt depth and villus height increased in five and six patients respectively. An earlier version of this page reported citrulline production as the outcome of that study; citrulline is not among its measured endpoints.

The teduglutide study in the same population (Gut 2005, 54:1224-1231, PMID 16099790) treated sixteen patients for 21 days across three dose levels. Pooled against baseline, absolute wet weight absorption rose 743 grams per day and relative absorption 22 percent, urine weight rose 555 grams per day and urine sodium 53 mmol per day, while faecal wet weight fell 711 grams per day and faecal energy excretion fell 808 kJ per day. In patients with an end jejunostomy, villus height rose 38 percent, crypt depth 22 percent and mitotic index 115 percent, while crypt depth and mitotic index were unchanged in colonic biopsies from patients with colon in continuity, a regional difference worth noting for anyone extrapolating small intestinal results to colon. The improvements reversed after the drug-free follow-up period, which is the clearest available statement that the trophic effect requires continued receptor occupancy rather than producing a durable structural change.

Interpretive Cautions for GLP-2 Studies

Three constraints recur in this literature. Species dependence is not a minor caveat here but the reason the analogue exists at all, given that the same peptide is trophic in mice and largely inert on bowel weight in wild-type rats. Morphometry and function can dissociate, so villus height gains should not be reported as absorptive gains without a balance or transport measurement alongside them. And the acute and chronic mechanisms are pharmacologically distinct, so an inhibitor that abolishes one may leave the other intact, which is the substance of the VPAC1 and IGF-1 receptor contrast above.

For material handling, GLP-2 and its [Gly2] analogue are linear peptides with no disulfide bonds. Methionine at position 10 of the native sequence is the residue to watch in oxidative stability work, and identity should be confirmed by mass against the intended sequence, since the native and [Gly2] forms differ by a single residue and therefore by a small and easily overlooked mass difference. General methodology is covered in the discussion of HPLC testing for peptide purity and in the treatment of mass spectrometry for identity confirmation.

Where a batch of a compound in our catalogue has been tested, the independent laboratory report is published on the certificates of analysis page, which also lists the compounds still awaiting a report. Neither GLP-2 nor teduglutide is a catalogue compound, and an earlier version of this page implied that both were available with certificates on file. Researchers comparing proglucagon-derived peptides may find the liraglutide GLP-1 receptor research overview useful for the incretin arm of the same precursor, and the research peptide catalogue and documentation section cover the compounds that are stocked.

Citations in this article were checked against the indexed PubMed record on 20 September 2026. Corrections made in this revision: the journal for the 1996 discovery paper, the direction of the position 2 substitution, the mechanism of the acute barrier effect, the outcome measures in Jeppesen 2001, and the replacement of untraceable citations attributed to Yusta 2000, Leen 2004, Tavares 2011 and Nakamura 2019 with the primary studies that report the underlying findings.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.